Gene therapy for lysosomal storage diseases

Molecular Therapy

Volumn 13, Issue 5, 2006, Pages 839-849

  Sands, Mark S ^a   Davidson, Beverly L ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GLUCURONIDASE; CARBOXYPEPTIDASE C; GLUCOSYLCERAMIDASE; LENTIVIRUS VECTOR; MICROSPHERE; PARVOVIRUS VECTOR; RETROVIRUS VECTOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DISEASE COURSE; DNA VECTOR; DRUG EFFICACY; DRUG TARGETING; FABRY DISEASE; FUCOSIDOSIS; GALACTOSIALIDOSIS; GAUCHER DISEASE; GENE EXPRESSION; GENE REPLACEMENT THERAPY; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; GRAFT VERSUS HOST REACTION; HUMAN; LYSOSOME STORAGE DISEASE; MANNOSIDOSIS; MYELOABLATIVE CONDITIONING; NIEMANN PICK DISEASE; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PHENOTYPE; PROMOTER REGION; REVIEW; SYSTEMIC THERAPY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LYSOSOMAL STORAGE DISEASES; MODELS, BIOLOGICAL;

ADENOVIRIDAE; LENTIVIRUS; PARVOVIRUS;

EID: 33645861655     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2006.01.006     Document Type: Review

References (148)

1. Neufeld E.F. Lysosomal storage diseases. Annu. Rev. Biochem. 60 (1991) 257-280
2. Scriver C.R. The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw-Hill, New York
3. Neufeld E.F., and Fratantoni J.C. Inborn errors of mucopolysaccharide metabolism. Science 169 (1970) 141-146
4. Kornfeld S. Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. Annu. Rev. Biochem. 61 (1992) 307-330
5. Achord D.T., Brot F.E., Bell C.E., and Sly W.S. Human beta-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 15 (1978) 269-278
6. Kakkis E.D., et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344 (2001) 182-188
7. Beutler E., et al. Enzyme replacement therapy for Gaucher disease. Blood 78 (1991) 1183-1189
8. Barton N.W., et al. Replacement therapy for inherited enzyme deficiency-Macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324 (1991) 1464-1470
9. Leimig T., et al. Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells. Blood 99 (2002) 3169-3178
10. Hahn C.N., del Pilar Martin M., Zhou X.Y., Mann L.W., and d'Azzo A. Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promoter. Proc. Natl. Acad. Sci. USA 95 (1998) 14880-14885
11. Davidson B.L., and Breakefield X.O. Viral vectors for gene delivery to the nervous system. Nat. Rev. Neurosci. 4 (2003) 353-364
12. Verma I.M., and Weitzman M.D. Gene therapy: twenty-first century medicine. Annu. Rev. Biochem. 74 (2005) 711-738
13. Fields B.N., and Knipe D.M. Fundamental Virology (1986), Raven Press, New York
14. Azzouz M., and Mazarakis N. Non-primate EIAV-based lentiviral vectors as gene delivery system for motor neuron diseases. Curr. Gene Ther. 4 (2004) 277-286
15. Kay M.A., Glorioso J.C., and Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7 (2001) 33-40
16. Johnston J.C., et al. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J. Virol. 73 (1999) 4991-5000
17. Stein C.S., and Davidson B.L. Gene transfer to the brain using feline immunodeficiency virus-based lentivirus vectors. Methods Enzymol. 346 (2002) 433-454
18. Rohll J.B., et al. Design, production, safety, evaluation, and clinical applications of nonprimate lentiviral vectors. Methods Enzymol. 346 (2002) 466-500
19. Abordo-Adesida E., et al. Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum. Gene Ther. 16 (2005) 741-751
20. Kang Y., et al. In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River virus glycoproteins. J. Virol. 76 (2002) 9378-9388
21. Stein C.S., Martins I., and Davidson B.L. The lymphocytic choriomeningitis virus envelope glycoprotein targets lentiviral gene transfer vector to neural progenitors in the murine brain. Mol. Ther. 11 (2005) 382-389
22. Wong L.F., et al. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol. Ther. 9 (2004) 101-111
23. Consiglio A., et al. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat. Med. 7 (2001) 310-316
24. Brooks A.I., et al. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc. Natl. Acad. Sci. USA 99 (2002) 6216-6221
25. Mitchell R.S., et al. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2 (2004) E234
26. + cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. Blood 105 (2005) 2699-2706
27. Hacein-Bey-Abina S., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
28. Hacein-Bey-Abina S., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348 (2003) 255-256
29. Yang Y., Jooss K.U., Su Q., Ertl H.C., and Wilson J.M. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3 (1996) 137-144
30. Stein C.S., Pemberton J.L., van Rooijen N., and Davidson B.L. Effects of macrophage depletion and anti-CD40 ligand on transgene expression and redosing with recombinant adenovirus. Gene Ther. 5 (1998) 431-439
31. Chiorini J.A., Yang L., Liu Y., Safer B., and Kotin R.M. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71 (1997) 6823-6833
32. Chiorini J.A., Kim F., Yang L., and Kotin R.M. Cloning and characterization of adeno-associated virus type 5. J. Virol. 73 (1999) 1309-1319
33. Schmidt M., Katano H., Bossis I., and Chiorini J.A. Cloning and characterization of a bovine adeno-associated virus. J. Virol. 78 (2004) 6509-6516
34. Gao G., Vandenberghe L.H., and Wilson J.M. New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5 (2005) 285-297
35. Walters R.W., et al. Structure of adeno-associated virus serotype 5. J. Virol. 78 (2004) 3361-3371
36. Padron E., et al. Structure of adeno-associated virus type 4. J. Virol. 79 (2005) 5047-5058
37. Davidson B.L., et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. USA 97 (2000) 3428-3432
38. Passini M.A., Watson D.J., Vite C.H., Landsburg D.J., Feigenbaum A.L., and Wolfe J.H. Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J. Virol. 77 (2003) 7034-7040
39. Zaiss A.K., and Muruve D.A. Immune responses to adeno-associated virus vectors. Curr. Gene Ther. 5 (2005) 323-331
40. Mastakov M.Y., Baer K., Symes C.W., Leichtlein C.B., Kotin R.M., and During M.J. Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain. J. Virol. 76 (2002) 8446-8454
41. Peden C.S., Burger C., Muzyczka N., and Mandel R.J. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J. Virol. 78 (2004) 6344-6359
42. Nakai H., Montini E., Fuess S., Storm T.A., Grompe M., and Kay M.A. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat. Genet. 34 (2003) 297-302
43. Krivit W., Peters C., and Shapiro E.G. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr. Opin Neurol. 12 (1999) 167-176
44. Staba S.L., et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N. Engl. J. Med. 350 (2004) 1960-1969
45. Walkley S.U., et al. Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease. Proc. Natl. Acad. Sci. USA 91 (1994) 2970-2974
46. Taylor R.M., Farrow B.R., Stewart G.J., and Healy P.J. Enzyme replacement in nervous tissue after allogeneic bone-marrow transplantation for fucosidosis in dogs. Lancet 2 (1986) 772-774
47. Breider M.A., Shull R.M., and Constantopoulos G. Long-term effects of bone marrow transplantation in dogs with mucopolysaccharidosis I. Am. J. Pathol. 134 (1989) 677-692
48. Miranda S.R., Erlich S., Friedrich Jr. V.L., Haskins M.E., Gatt S., and Schuchman E.H. Biochemical, pathological, and clinical response to transplantation of normal bone marrow cells into acid sphingomyelinase-deficient mice. Transplantation 65 (1998) 884-892
49. Sands M.S., et al. Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates. Lab. Invest. 68 (1993) 676-686
50. Sands M.S., Erway L.C., Vogler C., Sly W.S., and Birkenmeier E.H. Syngeneic bone marrow transplantation reduces the hearing loss associated with murine mucopolysaccharidosis type VII. Blood 86 (1995) 2033-2040
51. Birkenmeier E.H., et al. Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation. Blood 78 (1991) 3081-3092
52. Ohlemiller K.K., Vogler C.A., Roberts M., Galvin N., and Sands M.S. Retinal function is improved in a murine model of a lysosomal storage disease following bone marrow transplantation. Exp. Eye Res. 71 (2000) 469-481
53. Yeager A.M., Brennan S., Tiffany C., Moser H.W., and Santos G.W. Prolonged survival and remyelination after hematopoietic cell transplantation in the twitcher mouse. Science 225 (1984) 1052-1054
54. Hoogerbrugge P.M., Suzuki K., Poorthuis B.J., Kobayashi T., Wagemaker G., and van Bekkum D.W. Donor-derived cells in the central nervous system of twitcher mice after bone marrow transplantation. Science 239 (1988) 1035-1038
55. Follenzi A., Sabatino G., Lombardo A., Boccaccio C., and Naldini L. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum. Gene Ther. 13 (2002) 243-260
56. Consiglio A., et al. Robust in vivo gene transfer into adult mammalian neural stem cells by lentiviral vectors. Proc. Natl. Acad. Sci. USA 101 (2004) 14835-14840
57. Miranda S.R., Erlich S., Friedrich Jr. V.L., Gatt S., and Schuchman E.H. Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann-Pick disease. Gene Ther. 7 (2000) 1768-1776
58. Takenaka T., Qin G., Brady R.O., and Medin J.A. Circulating alpha-galactosidase A derived from transduced bone marrow cells: relevance for corrective gene transfer for Fabry disease. Hum. Gene Ther. 10 (1999) 1931-1939
59. Wolfe J.H., et al. Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature 360 (1992) 749-753
60. Zheng Y., Rozengurt N., Ryazantsev S., Kohn D.B., Satake N., and Neufeld E.F. Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. Mol. Genet. Metab. 79 (2003) 233-244
61. Malik P., Krall W.J., Yu X.J., Zhou C., and Kohn D.B. Retroviral-mediated gene expression in human myelomonocytic cells: a comparison of hematopoietic cell promoters to viral promoters. Blood 86 (1995) 2993-3005
62. Freeman B.J., Roberts M.S., Vogler C.A., Nicholes A., Hofling A.A., and Sands M.S. Behavior and therapeutic efficacy of beta-glucuronidase-positive mononuclear phagocytes in a murine model of mucopolysaccharidosis type VII. Blood 94 (1999) 2142-2150
63. Young P.P., Vogler C., Hofling A.A., and Sands M.S. Biodistribution and efficacy of donor T lymphocytes in a murine model of lysosomal storage disease. Mol. Ther. 7 (2003) 52-61
64. Zhou X.Y., et al. Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with overexpressing erythroid precursor cells. Genes Dev. 9 (1995) 2623-2634
65. + cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum. Gene Ther. 9 (1998) 2629-2640
66. Soper B.W., et al. Nonablative neonatal marrow transplantation attenuates functional and physical defects of beta-glucuronidase deficiency. Blood 97 (2001) 1498-1504
67. Barker J.E., Schuldt A.J., Lessard M.L., Jude C.D., Vogler C.A., and Soper B.W. Donor cell expansion is delayed following nonablative in utero transplantation to treat murine mucopolysaccharidosis type VII. Exp. Hematol. 31 (2003) 1112-1118
68. Qin G., et al. Preselective gene therapy for Fabry disease. Proc. Natl. Acad. Sci. USA 98 (2001) 3428-3433
69. + hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage disease. Mol. Ther. 9 (2004) 856-865
70. + cells leads to widespread distribution of donor-derived cells and correction of tissue pathology in a novel murine xenotransplantation model of lysosomal storage disease. Blood 101 (2003) 2054-2063
71. Biffi A., et al. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J. Clin. Invest. 113 (2004) 1118-1129
72. Moullier P., Bohl D., Heard J.M., and Danos O. Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts. Nat. Genet. 4 (1993) 154-159
73. Wolfe J.H., et al. Gene transfer of low levels of beta-glucuronidase corrects hepatic lysosomal storage in a large animal model of mucopolysaccharidosis VII. Mol. Ther. 2 (2000) 552-561
74. Ross C.J., Bastedo L., Maier S.A., Sands M.S., and Chang P.L. Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. Hum. Gene Ther. 11 (2000) 2117-2127
75. Liu C., Dunigan J.T., Watkins S.C., Bahnson A.B., and Barranger J.A. Long-term expression, systemic delivery, and macrophage uptake of recombinant human glucocerebrosidase in mice transplanted with genetically modified primary myoblasts. Hum. Gene Ther. 9 (1998) 2375-2384
76. Kosuga M., et al. Engraftment of genetically engineered amniotic epithelial cells corrects lysosomal storage in multiple areas of the brain in mucopolysaccharidosis type VII mice. Mol. Ther. 3 (2001) 139-148
77. Stein C.S., Ghodsi A., Derksen T., and Davidson B.L. Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. J. Virol. 73 (1999) 3424-3429
78. Peltola M., et al. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse. Gene Ther. 5 (1998) 1314-1321
79. Ohashi T., Watabe K., Uehara K., Sly W.S., Vogler C., and Eto Y. Adenovirus-mediated gene transfer and expression of human beta-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice. Proc. Natl. Acad. Sci. USA 94 (1997) 1287-1292
80. Ziegler R.J., et al. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. Hum. Gene Ther. 10 (1999) 1667-1682
81. Amalfitano A., et al. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc. Natl. Acad. Sci. USA 96 (1999) 8861-8866
82. Du H., Heur M., Witte D.P., Ameis D., and Grabowski G.A. Lysosomal acid lipase deficiency: correction of lipid storage by adenovirus-mediated gene transfer in mice. Hum. Gene Ther. 13 (2002) 1361-1372
83. Kosuga M., et al. Adenovirus-mediated gene therapy for mucopolysaccharidosis VII: involvement of cross-correction in wide-spread distribution of the gene products and long-term effects of CTLA-4Ig coexpression. Mol. Ther. 1 (2000) 406-413
84. Xu F., et al. Glycogen storage in multiple muscles of old GSD-II mice can be rapidly cleared after a single intravenous injection with a modified adenoviral vector expressing hGAA. J. Gene Med. 7 (2005) 171-178
85. Hermonat P.L., and Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc. Natl. Acad. Sci. USA 81 (1984) 6466-6470
86. Fraites Jr. T.J., et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol. Ther. 5 (2002) 571-578
87. Takahashi H., et al. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc. Natl. Acad. Sci. USA 99 (2002) 13777-13782
88. Watson G.L., et al. Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. Gene Ther. 5 (1998) 1642-1649
89. Daly T.M., Okuyama T., Vogler C., Haskins M.E., Muzyczka N., and Sands M.S. Neonatal intramuscular injection with recombinant adeno-associated virus results in prolonged beta-glucuronidase expression in situ and correction of liver pathology in mucopolysaccharidosis type VII mice. Hum. Gene Ther. 10 (1999) 85-94
90. Sferra T.J., Backstrom K., Wang C., Rennard R., Miller M., and Hu Y. Widespread correction of lysosomal storage following intrahepatic injection of a recombinant adeno-associated virus in the adult MPS VII mouse. Mol. Ther. 10 (2004) 478-491
91. Jung S.C., et al. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc. Natl. Acad. Sci. USA 98 (2001) 2676-2681
92. Sun B., et al. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol. Ther. 11 (2005) 57-65
93. Daly T.M., Vogler C., Levy B., Haskins M.E., and Sands M.S. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc. Natl. Acad. Sci. USA 96 (1999) 2296-2300
94. Daly T.M., Ohlemiller K.K., Roberts M.S., Vogler C.A., and Sands M.S. Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther. 8 (2001) 1291-1298
95. Hartung S.D., et al. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human α-l-iduronidase gene. Mol. Ther. 9 (2004) 866-875
96. Stein C.S., et al. In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. Mol. Ther. 3 (2001) 850-856
97. Kobayashi H., et al. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol. Ther. 11 (2005) 776-789
98. Di Natale P., et al. Treatment of the mouse model of mucopolysaccharidosis type IIIB with lentiviral-NAGLU vector. Biochem. J. 388 (2005) 639-646
99. Gao C., Sands M.S., Haskins M.E., and Ponder K.P. Delivery of a retroviral vector expressing human beta-glucuronidase to the liver and spleen decreases lysosomal storage in mucopolysaccharidosis VII mice. Mol. Ther. 2 (2000) 233-244
100. Ponder K.P., et al. Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc. Natl. Acad. Sci. USA 99 (2002) 13102-13107
101. Przybylska M., et al. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors. J. Gene Med. 6 (2004) 85-92
102. Li T., and Davidson B.L. Phenotype correction in retinal pigment epithelium in murine mucopolysaccharidosis VII by adenovirus-mediated gene transfer. Proc. Natl. Acad. Sci. USA 92 (1995) 7700-7704
103. Ho T.T., et al. Phenotypic rescue after adeno-associated virus-mediated delivery of 4-sulfatase to the retinal pigment epithelium of feline mucopolysaccharidosis VI. J. Gene Med. 4 (2002) 613-621
104. Hennig A.K., Ogilvie J.M., Ohlemiller K.K., Timmers A.M., Hauswirth W.W., and Sands M.S. AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS VII mice. Mol. Ther. 10 (2004) 106-116
105. Griffey M., Macauley S.L., Ogilvie J.M., and Sands M.S. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol. Ther. 12 (2005) 413-421
106. Franco L.M., et al. Evasion of immune responses to introduced human acid α-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol. Ther. 12 (2005) 876-884
107. Barbon C.M., et al. AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick disease. Mol. Ther. 12 (2005) 431-440
108. Savas P.S., Hemsley K.M., and Hopwood J.J. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. Mol. Genet. Metab. 82 (2004) 273-285
109. Taylor R.M., and Wolfe J.H. Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase. Nat. Med. 3 (1997) 771-774
110. Sakurai K., et al. Brain transplantation of genetically modified bone marrow stromal cells corrects CNS pathology and cognitive function in MPS VII mice. Gene Ther. 11 (2004) 1475-1481
111. Snyder E.Y., Taylor R.M., and Wolfe J.H. Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature 374 (1995) 367-370
112. Buchet D., Serguera C., Zennou V., Charneau P., and Mallet J. Long-term expression of β-glucuronidase by genetically modified human neural progenitor cells grafted into the mouse central nervous system. Mol. Cell. Neurosci. 19 (2002) 389-401
113. Bourgoin C., et al. Widespread distribution of beta-hexosaminidase activity in the brain of a Sandhoff mouse model after coinjection of adenoviral vector and mannitol. Gene Ther. 10 (2003) 1841-1849
114. Fu H., Samulski R.J., McCown T.J., Picornell Y.J., Fletcher D., and Muenzer J. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Mol. Ther. 5 (2002) 42-49
115. Passini M.A., et al. Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. J. Neurosci. 26 (2006) 1334-1342
116. Frisella W.A., et al. Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. Mol. Ther. 3 (2001) 351-358
117. Rafi M.A., et al. AAV-mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy. Mol. Ther. 11 (2005) 734-744
118. Passini M.A., et al. AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease. Mol. Ther. 11 (2005) 754-762
119. Vite C.H., et al. Effective gene therapy for an inherited CNS disease in a large animal model. Ann. Neurol. 57 (2005) 355-364
120. Liu G., Martins I., Wemmie J.A., Chiorini J.A., and Davidson B.L. Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J. Neurosci. 25 (2005) 9321-9327
121. Bosch A., Perret E., Desmaris N., Trono D., and Heard J.M. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum. Gene Ther. 11 (2000) 1139-1150
122. Bosch A., Perret E., Desmaris N., and Heard J.M. Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol. Ther. 1 (2000) 63-70
123. Ghodsi A., Stein C., Derksen T., Yang G., Anderson R.D., and Davidson B.L. Extensive beta-glucuronidase activity in murine central nervous system after adenovirus-mediated gene transfer to brain. Hum. Gene Ther. 9 (1998) 2331-2340
124. Haskell R.E., Hughes S.M., Chiorini J.A., Alisky J.M., and Davidson B.L. Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-I to the mouse central nervous system. Gene Ther. 10 (2003) 34-42
125. Hennig A.K., et al. Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. J. Neurosci. 23 (2003) 3302-3307
126. Desmaris N., Verot L., Puech J.P., Caillaud C., Vanier M.T., and Heard J.M. Prevention of neuropathology in the mouse model of Hurler syndrome. Ann. Neurol. 56 (2004) 68-76
127. Xia H., Mao Q., and Davidson B.L. The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. Nat. Biotechnol. 19 (2001) 640-644
128. Orii K.O., et al. Defining the pathway for Tat-mediated delivery of β-glucuronidase in cultured cells and MPS VII mice. Mol. Ther. 12 (2005) 345-352
129. Elliger S.S., Elliger C.A., Lang C., and Watson G.L. Enhanced secretion and uptake of β-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice. Mol. Ther. 5 (2002) 617-626
130. Sanftner L.M., et al. AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters. Exp. Neurol. 194 (2005) 476-483
131. Krauze M.T., et al. Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp. Neurol. 196 (2005) 104-111
132. Watson D.J., Passini M.A., and Wolfe J.H. Transduction of the choroid plexus and ependyma in neonatal mouse brain by vesicular stomatitis virus glycoprotein-pseudotyped lentivirus and adeno-associated virus type 5 vectors. Hum. Gene Ther. 16 (2005) 49-56
133. Burger C., et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 10 (2004) 302-317
134. Shen J.S., Watabe K., Ohashi T., and Eto Y. Intraventricular administration of recombinant adenovirus to neonatal twitcher mouse leads to clinicopathological improvements. Gene Ther. 8 (2001) 1081-1087
135. Lin D., et al. AAV2/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2. Mol. Ther. 12 (2005) 422-430
136. Buckley R.H. Gene therapy for SCID-A complication after remarkable progress. Lancet 360 (2002) 1185-1186
137. Check E. A tragic setback. Nature 420 (2002) 116-118
138. Donsante A., et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther. 8 (2001) 1343-1346
139. Vogler C., et al. Transgene produces massive overexpression of human beta-glucuronidase in mice, lysosomal storage of enzyme, and strain-dependent tumors. Proc. Natl. Acad. Sci. USA 100 (2003) 2669-2673
140. Takaura N., et al. Attenuation of ganglioside GM1 accumulation in the brain of GM1 gangliosidosis mice by neonatal intravenous gene transfer. Gene Ther. 10 (2003) 1487-1493
141. Norflus F., et al. Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice. J. Clin. Invest. 101 (1998) 1881-1888
142. Kyrkanides S., Miller J.H., Brouxhon S.M., Olschowka J.A., and Federoff H.J. Beta-hexosaminidase lentiviral vectors: transfer into the CNS via systemic administration. Brain Res. Mol. Brain Res. 133 (2005) 286-298
143. Arfi A., et al. Bicistronic lentiviral vector corrects β-hexosaminidase deficiency in transduced and cross-corrected human Sandhoff fibroblasts. Neurobiol. Dis. 20 (2005) 583-593
144. Di Domenico C., et al. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector. Hum. Gene Ther. 16 (2005) 81-90
145. Cressant A., et al. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. J. Neurosci. 24 (2004) 10229-10239
146. Sondhi D., et al. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Ther. 12 (2005) 1618-1632
147. Crystal R.G., et al. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum. Gene Ther. 15 (2004) 1131-1154
148. Griffey M., et al. Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 16 (2004) 360-369